论文部分内容阅读
目的:分析肺结核伴糖尿病采用胸腺肽α1联合短程化疗治疗的临床效果。方法:使用随机分组法将我院收治的88例肺结核伴糖尿病患者分为治疗组(44例)和对照组(44例),对照组予以短程化疗,并控制血糖,治疗组在此基础上联合胸腺肽α1治疗,分析其治疗效果。结果:治疗组病灶吸收有效率为93.2%,对照组有效率为75.0%,两组间对比P<0.05。治疗组痰菌转阴率高于对照组(P<0.05),患者治疗期间无严重不良反应。结论:胸腺肽α1联合短程化疗治疗肺结核伴糖尿病取得让人满意的临床效果,明显促进病变吸收,提高机体免疫力,值得临床肯定。
Objective: To analyze the clinical effect of thymosin α1 combined with short-course chemotherapy in the treatment of pulmonary tuberculosis complicated with diabetes mellitus. Methods: 88 patients with tuberculosis and diabetes mellitus admitted to our hospital were divided into treatment group (44 cases) and control group (44 cases) by random grouping method. The control group was given short-term chemotherapy and blood sugar control. On the basis of this, the treatment group was united Thymosin α1 treatment, analysis of its therapeutic effect. Results: The effective rate of absorption in the treatment group was 93.2% and that in the control group was 75.0%, P <0.05 between the two groups. The negative rate of sputum in the treatment group was higher than that in the control group (P <0.05). There was no serious adverse reaction during the treatment. Conclusion: Thymosin α1 combined with short-course chemotherapy in the treatment of pulmonary tuberculosis with diabetes achieved satisfactory clinical results, significantly promote the absorption of lesions and improve immunity, deserving clinical affirmation.